The role of type I interferon in the treatment of COVID‐19

F Sodeifian, M Nikfarjam, N Kian… - Journal of medical …, 2022 - Wiley Online Library
Although significant research has been done to find effective drugs against coronavirus
disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 …

Inflammatory pathways in COVID‐19: mechanism and therapeutic interventions

Y Jiang, T Zhao, X Zhou, Y **ang… - MedComm, 2022 - Wiley Online Library
Abstract The 2019 coronavirus disease (COVID‐19) pandemic has become a global crisis.
In the immunopathogenesis of COVID‐19, SARS‐CoV‐2 infection induces an excessive …

Pathogenesis and treatment of cytokine storm in COVID-19

M Soy, G Keser, MP Atagündüz - Turkish Journal of Biology, 2021 - journals.tubitak.gov.tr
COVID-19 is a viral infection caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) that killed a large number of patients around the world. A hyperinflammatory …

Beyond vaccines: clinical status of prospective COVID-19 therapeutics

S Kumar, DM Çalışkan, J Janowski, A Faist… - Frontiers in …, 2021 - frontiersin.org
Since November 2019 the SARS-CoV-2 pandemic has caused nearly 200 million infection
and more than 4 million deaths globally (Updated information from the World Health …

Therapeutic role of immunomodulators during the COVID-19 pandemic–a narrative review

H Al-Hajeri, F Baroun, F Abutiban… - Postgraduate …, 2022 - Taylor & Francis
The emergency state caused by COVID-19 saw the use of immunomodulators despite the
absence of robust research. To date, the results of relatively few randomized controlled trials …

Exploiting natural antiviral immunity for the control of pandemics: lessons from Covid-19

E Aricò, L Bracci, L Castiello, F Urbani… - Cytokine & growth factor …, 2022 - Elsevier
The outbreak of coronavirus disease 2019 (COVID-19), triggered by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), and the disruptive global consequences …

COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now–New Hopes?

JJ Vanden Eynde - Pharmaceuticals, 2021 - mdpi.com
The DisCoVeRy clinical trial aimed at the evaluation of four treatments for patients suffering
from severe to critical COVID-19: Hydroxychloroquine, eventually associated with …

The effectiveness of dexamethasone as a combination therapy for COVID-19

N Namazi - Acta Pharmaceutica, 2022 - hrcak.srce.hr
Sažetak Coronavirus disease 2019 (COVID-19) was reported as a global pandemic in
March 2020 after invading many countries and leaving behind tens of thousands of infected …

[HTML][HTML] Effect of anti-COVID-19 drugs on patients with cancer

W Huang, W Liu, T Yu, Z Zhang, L Zhai… - European Journal of …, 2024 - Elsevier
The clinical treatment of patients with cancer who are also diagnosed with coronavirus
disease (COVID-19) has been a challenging issue since the outbreak of COVID-19 …

Potential implications of a type 1 interferon gene signature on covid-19 severity and chronic inflammation in sickle cell disease

E Madany, D Okwan-Duodu, R Balbuena-Merle… - Frontiers in …, 2021 - frontiersin.org
At the onset of the corona virus disease 19 (COVID-19) pandemic, there were concerns that
patients with sickle cell disease (SCD) might be especially vulnerable to severe sequelae of …